Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 23, 2014, Pages 5478-5483

  Azimioara, Mihai ^a   Alper, Phil ^a   Cow, Christopher ^a   Mutnick, Daniel ^a   Nikulin, Victor ^a   Lelais, Gerald ^a   Mecom, John ^a   McNeill, Matthew ^a   Michellys, Pierre Yves ^a   Wang, Zhiliang ^a   Reding, Esther ^a   Paliotti, Michael ^a   Li, Jing ^a   Bao, Dingjiu ^a   Zoll, Jocelyn ^a   Kim, Young ^a   Zimmerman, Matthew ^a   Groessl, Todd ^a   Tuntland, Tove ^a   Joseph, Sean B ^a   McNamara, Peter ^a   Seidel, H Martin ^a   Epple, Robert ^a   more..

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

GPCR agonists; GPR119; Tricyclic pyrazolopyrimidines; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; PYRAZOLOPYRIMIDINE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GPR119 PROTEIN, HUMAN; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG CLEARANCE; DRUG CONFORMATION; DRUG EFFICACY; DRUG ISOLATION; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; INSULIN RELEASE; LIVER CLEARANCE; MICROSOME; MOUSE; NONHUMAN; NUCLEOPHILICITY; ORAL GLUCOSE TOLERANCE TEST; PHARMACOPHORE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; DRUG EFFECTS; SYNTHESIS;

ANIMALS; DRUG DISCOVERY; MICE; MOLECULAR STRUCTURE; PYRIMIDINES; RATS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84910118728     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.10.010     Document Type: Article

References (13)

1. A. Ichimura, A. Hirasawa, T. Hara, and G. Tsujimoto Prostaglandins Other Lipid Mediat. 89 2009 82
2. Y. Itoh Nature 422 2003 173
3. A.D. Mancini, and V. Poitouts Trends Endocrinol. Metabol. 24 2013 398
4. D.J. Drucker, and M.A. Nauck Lancet 368 2006 1696
5. H.A. Overton, M.C. Fyfe, and C. Reynet Br. J. Pharmacol. 153 2008 S76
6. H. Lan, H.V. Lin, C.F. Wang, M.J. Wright, S. Xu, L. Kang, K. Juhl, J.A. Hedrick, and T.J. Kowalski Br. J. Pharmacol. 165 2012 2799
7. H.S. Hansen, M.M. Rosenkilde, J.J. Holst, and T.W. Schwartz Trends Pharmacol. Sci. 33 2012 374
8. T. Ohishi, and Y. Shigeru Expert Opin. Invest. Drugs 21 2012 321
9. P. Alper, M. Azimioara, C. Cow, D. Mutnick, V. Nikulin, P.-Y. Michellys, Z. Wang, E. Reding, M. Paliotti, J. Li, D. Bao, J. Zoll, Y. Kim, M. Zimmerman, T. Groessel, T. Tuntland, S.B. Joseph, P. McNamara, H.M. Seidel, and R. Epple Bioorg. Med Chem. Lett. 24 2014 2383
10. G.F. Semple, B. Fioravanti, G. Pereira, I. Calderon, J. Uy, K. Choi, Y. Xiong, A. Ren, M. Morgan, D. Dave, W. Thomsen, D.J. Unett, C. Xing, S. Bossie, C. Carroll, Z.-L. Chu, A.J. Grottick, E.K. Hauser, J. Leonard, and R.M. Jones J. Med. Chem. 51 2008 5172
11. H.A. Overton, A.J. Babbs, S.M. Doel, M.C.T. Fyfe, L.S. Gardner, G. Griffin, H.C. Jackson, M.J. Procter, C.M. Rasamison, M. Tang-Christensen, P.S. Widdowson, G.M. Williams, and C. Reynet Cell Metab. 3 2006 167
12. X. Zhu, X. Zhu, D. Huang, X. Lan, C. Tang, Y. Zhu, J. Han, W. Huang, and H. Qian Eur. J. Med. Chem. 46 2011 2901
13. 2, the (R) enantiomer is (-) levorotatory; see Deng, Q. -H.; Wadepohl, H; Gade, L. H., J. Am. Chem. Soc. 2012, 134, 2946 and references therein].